Drug Delivery: Advances in drug delivery vehicles and devices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Drug Delivery
Tablets & capsules, liquid-dosage forms. Inhalables & intranasals. Injectables: intravenous, intramuscular & subcutaneous. Nanotechnology, dissolvable films and tablets & radio frequency transdermal drug delivery.

Advances in Controlled-Release Drug Delivery

June 2, 2014

Pharmaceutical Technology

Industry experts share their perspectives on key advances in controlled-release drug delivery and future innovations in this arena.

Boosting New Antibiotic Drug Development in Europe

May 2, 2014

Pharmaceutical Technology

With the rising threat of antibiotic resistance and a diminishing R&D pipeline for novel drugs, Europe must step up its game to address this growing problem.

Packaging Becomes Enabler for Biopharmaceuticals

May 2, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

Once an afterthought, packaging has now become an essential component of biopharmaceutical product development and marketing.

The Benefits of eClinical Systems in Supply-Chain Management

April 2, 2014

Pharmaceutical Technology

Kurt Lumsden, Director, eCDS Client Services at PAREXEL Informatics, discusses eClinical supply-chain management.

Drug Delivery Technologies Provide Growth Opportunities for Biopharmaceuticals

April 1, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

Advanced drug delivery technologies can increase efficacy and safety, extend patent lives, and provide competitive differentiation for biopharmaceuticals.

UK Biotech Gains Momentum

March 12, 2014

Pharmaceutical Technology

To gain insights into the current trends of the biotechnology sector in the United Kingdom, Pharmaceutical Technology Europe spoke with Steve Bates, chief executive officer of the BioIndustry Association (BIA), the trade association for biotech companies in the UK.

Nanosimilars and follow-on nanomedicines

March 2, 2014

Pharmaceutical Technology

With nanomedicines on the rise, a new class of non-biological complex drugs (NBCDs), which include nanosimilars, has emerged. As drug regulators are faced with the challenge of defining a framework to ensure the safe introduction of the follow-on nano-therapeutics, Stefan Muhlebach explains why NBCDs cannot be assessed using the standard generic or biosimilar approaches.

Characterization of nanomedicines

March 2, 2014

Pharmaceutical Technology

Nanomedicines can offer promising benefits in the diagnosis and treatment of diseases but there are still concerns about the safety and quality of these therapeutics partly because of the lack of clear regulatory guidance. Scott McNeil, PhD, director of the Nanotechnology Characterization Laboratory (NCL), spoke with Pharmaceutical Technology about nanomedicine characterization.

Current issues with nanomedicines

March 2, 2014

Pharmaceutical Technology

Despite the progress made in nanomedicine development, there are several issues that remain unresolved. Raj Bawa, PhD, provides insight.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here